To the Editor The recent meta-analysis from Cénat et al1 revealed that the estimated pooled prevalence of COVID-19–associated posttraumatic stress disorder (PTSD) was almost 22%. However, prior to the study by Janiri and colleagues,2 no study to our knowledge had confirmed PTSD diagnoses among patients using a structured clinician-administered diagnostic interview, such as the Clinician Administered PTSD Scale for DSM-5 (CAPS-5).3 We commend Janiri et al2 for applying rigorous diagnostic methods to better determine PTSD prevalence among COVID-19 survivors. Knowing which COVID-19 survivors are experiencing clinically significant PTSD and other psychiatric symptoms is important for allocating appropriate mental health resources.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Marx BP, Schnurr PP, Friedman MJ. Improving the Assessment of COVID-19–Associated Posttraumatic Stress Disorder. JAMA Psychiatry. 2021;78(7):795. doi:10.1001/jamapsychiatry.2021.1123
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.